TCGA-A8-A07O-01A-11R-A00Z-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 10
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.730
- E2F_TARGETS+0.630
- G2M_CHECKPOINT+0.580
- MYC_TARGETS_V1+0.580
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- MITOTIC_SPINDLE+0.350
- MTORC1_SIGNALING+0.350
- INFLAMMATORY_RESPONSE+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.310
- GLYCOLYSIS+0.280
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.340
- ESTROGEN_RESPONSE_EARLY-0.240
- BILE_ACID_METABOLISM-0.210
- COAGULATION-0.190
- TGF_BETA_SIGNALING-0.190
- UV_RESPONSE_DN-0.190
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.180
- MYOGENESIS-0.180
- ESTROGEN_RESPONSE_LATE-0.160
- P53_PATHWAY-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR35579844 | — | E | 0.893 |
| 2 | TCGA-AR-A256-01A-11R-A169-07 | — | E | 0.858 |
| 3 | TCGA-D8-A143-01A-11R-A115-07 | — | C | 0.848 |
| 4 | TCGA-A1-A0SP-01A-11R-A084-07 | — | E | 0.830 |
| 5 | MNG922 | — | — | 0.830 |
| 6 | de5a4588-05ec-461f-9235-90611b01f4b6 | — | — | 0.828 |
| 7 | SRR1313139 | — | E | 0.825 |
| 8 | SRR8518152 | — | E | 0.824 |
| 9 | TCGA-D8-A1JM-01A-11R-A13Q-07 | — | E | 0.823 |
| 10 | TCGA-EW-A1P8-01A-11R-A144-07 | — | E | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.730 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.630 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.580 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.580 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |